

Basic science: (MAY 2007)

1. Adamovic T, Roshani L, Chen L, Schaffer BS, Helou K, Levan G, Olsson B, Shull JD. Non-random pattern of chromosome aberrations in 17 β -estradiol-induced rat mammary tumors: indications of distinct pathways for tumor development. *Genes Chromosomes Cancer* 2007; **46**: 459–469.
2. Adams BD, Furneaux H, White BA. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor- α (ER α) and represses ER α messenger RNA and protein expression in breast cancer cell lines. *Mol Endocrinol* 2007; **21**: 1132–1147.
3. Aupperlee MD, Haslam SZ. Differential hormonal regulation and function of progesterone receptor isoforms in normal adult mouse mammary gland. *Endocrinology* 2007; **148**: 2290–2300.
4. Borgquist S, Anagnostaki L, Jirstrom K, Landberg G, Manjer J. Breast tumours following combined hormone replacement therapy express favourable prognostic factors. *Int J Cancer* 2007; **120**: 2202–2207.
5. Holst F, Stahl PR, Ruiz C, Hellwinkel O, Jehan Z, Wendland M, Lebeau A, Terracciano L, Al-Kuraya K, Janicke F, Sauter G, Simon R. Estrogen receptor α (ESR1) gene amplification is frequent in breast cancer. *Nat Genet* 2007; **39**: 655–660.
6. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, Wacholder S, Wang Z, Welch R, Hutchinson A, Wang J, Yu K, Chatterjee N, Orr N, Willett WC, Colditz GA, Ziegler RG, Berg CD, Buys SS, McCarty CA, Feigelson HS, Calle EE, Thun MJ, Hayes RB, Tucker M, Gerhard DS, Fraumeni JF, Hoover RN, Thomas G, Chanock SJ. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. *Nat Genet* 2007; **39**: 870–874.
7. Kim H, Chen JJ, Yu XH. Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response. *Science* 2007; **316**: 1202–1205.
8. Li W, Xiao C, Vonderhaar BK, Deng CX. A role of estrogen/ER α signaling in BRCA1-associated tissue-specific tumor formation. *Oncogene* 2007 May 14; [Epub ahead of print], doi:10.1038/sj.onc.1210527.
9. Liu BL, Ordonez-Ercan D, Fan ZY, Edgerton SM, Yang XH, Thor AD. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. *Int J Cancer* 2007; **120**: 1874–1882.
10. Maiello MR, D'Alessio A, De Luca A, Carotenuto A, Rachiglio AM, Napolitano M, Cito L, Guzzo A, Normanno N. AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib. *Breast Cancer Res Treat* 2007; **102**: 275–282.
11. McBryan J, Howlin J, Kenny PA, Shioda T, Martin F. ER α -CITED1 co-regulated genes expressed during pubertal mammary gland development: implications for breast cancer prognosis. *Oncogene* 2007 May 7; [Epub ahead of print], doi:10.1038/sj.onc.1210468.
12. Monaco SE, Angelastro JM, Szabolcs M, Greene LA. The transcription factor ATF5 is widely expressed in carcinomas, and interference with its function selectively kills neoplastic, but not nontransformed, breast cell lines. *Int J Cancer* 2007; **120**: 1883–1890.
13. Paterson AL, Pole JCM, Blood KA, Garcia MJ, Cooke SL, Teschendorff AE, Wang YZ, Chin SF, Ylstra B, Caldas C, Edwards PAW. Co-amplification of 8p 12 and 11q 13 in breast cancers is not the result of a single genomic event. *Genes Chromosomes Cancer* 2007; **46**: 427–439.
14. Pellikainen JM, Kosma VM. Activator protein-2 in carcinogenesis with a special reference to breast cancer – A mini review. *Int J Cancer* 2007; **120**: 2061–2067.

15. Ross JS, Symmans WF, Pusztai L, Fiortobagyi GN. Standardizing slide-based assays in breast cancer: hormone receptors, HER2, and sentinel lymph nodes. *Clin Cancer Res* 2007; **13**: 2831–2835.
16. Sabnis G, Goloubeva O, Jelovac D, Schayowitz A, Brodie A. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens. *Clin Cancer Res* 2007; **13**: 2751–2757.
17. Sirvent A, Boureux A, Simon V, Leroy C, Roche S. The tyrosine kinase Abl is required for Src-transforming activity in mouse fibroblasts and human breast cancer cells. *Oncogene* 2007 May 28; [Epub ahead of print], doi:10.1038/sj.onc.1210543.
18. Sobhian B, Shao GZ, Lilli DR, Culhane AC, Moreau LA, Xia B, Livingston DM, Greenberg RA. RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites. *Science* 2007; **316**: 1198–1202.
19. Stacey SN, Manolescu A, Sulem P, Rafnar T, Gudmundsson J, Gudjonsson SA, Masson G, Jakobsdottir M, Thorlacius S, Helgason A, Aben KK, Strobbe LJ, Albers-Akkers MT, Swinkels DW, Henderson BE, Kolonel LN, Le Marchand L, Millastre E, Andres R, Godino J, Garcia-Prats MD, Polo E, Tres A, Mouy M, Saemundsdottir J, Backman VM, Gudmundsson L, Kristjansson K, Bergthorsson JT, Kostic J, Frigge ML, Geller F, Gudbjartsson D, Sigurdsson H, Jonsdottir T, Hrafnkelsson J, Johannsson J, Sveinsson T, Myrdal G, Grimsson HN, Jonsson T, von Holst S, Werelius B, Margolin S, Lindblom A, Mayor-domo JI, Haiman CA, Kiemeny LA, Johannsson OT, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. *Nat Genet* 2007; **39**: 865–869.
20. Ursini-Siegel J, Schade B, Muller WJ, Cardiff RD. Timeline – insights from transgenic mouse models of ERBB2-induced breast cancer. *Nat Rev Cancer* 2007; **7**: 389–397.
21. Wang X, Liu L, Montagna C, Ried T, Deng CX. Haploinsufficiency of Parp1 accelerates Brca1-associated centrosome amplification, telomere shortening, genetic instability, apoptosis, and embryonic lethality. *Cell Death Differ* 2007; **14**: 924–931.

*Prepared by
R Sutherland
Cancer Research Program
Garvan Institute of Medical Research
Darlinghurst, NSW, Australia*